Cargando…
Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases
INTRODUCTION: Catecholamine-resistant vasoplegia is a potentially devastating complication during liver transplantation. Hydroxocobalamin has emerged as a treatment for vasoplegia associated with cardiac surgery, liver transplantation, and septic shock. PRESENTATION OF CASE: We performed a retrospec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399471/ https://www.ncbi.nlm.nih.gov/pubmed/35981485 http://dx.doi.org/10.1016/j.ijscr.2022.107488 |
_version_ | 1784772529299128320 |
---|---|
author | Boettcher, Brent T. Woehlck, Harvey J. Makker, Hemanckur Pagel, Paul S. Freed, Julie K. |
author_facet | Boettcher, Brent T. Woehlck, Harvey J. Makker, Hemanckur Pagel, Paul S. Freed, Julie K. |
author_sort | Boettcher, Brent T. |
collection | PubMed |
description | INTRODUCTION: Catecholamine-resistant vasoplegia is a potentially devastating complication during liver transplantation. Hydroxocobalamin has emerged as a treatment for vasoplegia associated with cardiac surgery, liver transplantation, and septic shock. PRESENTATION OF CASE: We performed a retrospective review of patients who underwent liver transplantation between October 2015 and May 2020 to evaluate the efficiency of hydroxocobalamin in this setting. DISCUSSION: A total of 137 patients underwent liver transplantation, of which 20 received hydroxocobalamin for vasoplegia. Administration of hydroxocobalamin increased mean arterial pressure and reduced vasoactive drug requirements. CONCLUSION: This case series adds to the previous individual reports describing the use of hydroxocobalamin during liver transplantation suggesting hydroxocobalamin can mitigate refractory hypotension from catecholamine resistant vasoplegia during liver transplantation. |
format | Online Article Text |
id | pubmed-9399471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93994712022-08-25 Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases Boettcher, Brent T. Woehlck, Harvey J. Makker, Hemanckur Pagel, Paul S. Freed, Julie K. Int J Surg Case Rep Case Series INTRODUCTION: Catecholamine-resistant vasoplegia is a potentially devastating complication during liver transplantation. Hydroxocobalamin has emerged as a treatment for vasoplegia associated with cardiac surgery, liver transplantation, and septic shock. PRESENTATION OF CASE: We performed a retrospective review of patients who underwent liver transplantation between October 2015 and May 2020 to evaluate the efficiency of hydroxocobalamin in this setting. DISCUSSION: A total of 137 patients underwent liver transplantation, of which 20 received hydroxocobalamin for vasoplegia. Administration of hydroxocobalamin increased mean arterial pressure and reduced vasoactive drug requirements. CONCLUSION: This case series adds to the previous individual reports describing the use of hydroxocobalamin during liver transplantation suggesting hydroxocobalamin can mitigate refractory hypotension from catecholamine resistant vasoplegia during liver transplantation. Elsevier 2022-08-10 /pmc/articles/PMC9399471/ /pubmed/35981485 http://dx.doi.org/10.1016/j.ijscr.2022.107488 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Series Boettcher, Brent T. Woehlck, Harvey J. Makker, Hemanckur Pagel, Paul S. Freed, Julie K. Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title | Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title_full | Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title_fullStr | Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title_full_unstemmed | Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title_short | Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases |
title_sort | hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: a single-center series of 20 cases |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399471/ https://www.ncbi.nlm.nih.gov/pubmed/35981485 http://dx.doi.org/10.1016/j.ijscr.2022.107488 |
work_keys_str_mv | AT boettcherbrentt hydroxocobalaminfortreatmentofcatecholamineresistantvasoplegiaduringlivertransplantationasinglecenterseriesof20cases AT woehlckharveyj hydroxocobalaminfortreatmentofcatecholamineresistantvasoplegiaduringlivertransplantationasinglecenterseriesof20cases AT makkerhemanckur hydroxocobalaminfortreatmentofcatecholamineresistantvasoplegiaduringlivertransplantationasinglecenterseriesof20cases AT pagelpauls hydroxocobalaminfortreatmentofcatecholamineresistantvasoplegiaduringlivertransplantationasinglecenterseriesof20cases AT freedjuliek hydroxocobalaminfortreatmentofcatecholamineresistantvasoplegiaduringlivertransplantationasinglecenterseriesof20cases |